Comparison of longitudinal and cumulative toxicity associated with targeted therapy versus chemotherapy for advanced EGFR-mutant NSCLC: post-hoc analysis of LUX-Lung 3
Publication date: Available online 27 October 2026 Source: JTO Clinical and Research Reports Author(s): William J. Phillips, Vida Alami, Dexiang Gao, Alexander S. Watson, D.Ross Camidge
Comparison of longitudinal and cumulative toxicity associated with targeted therapy versus chemotherapy for advanced EGFR-mutant NSCLC: post-hoc analysis of LUX-Lung 3. // JTO Clinical and Research Reports. – URL: https://www.sciencedirect.com/science/article/pii/S2666364326001578?dgcid=rss_sd_all
Comparison of longitudinal and cumulative toxicity associated with targeted therapy versus chemotherapy for advanced EGFR-mutant NSCLC: post-hoc analysis of LUX-Lung 3. JTO Clinical and Research Reports. https://www.sciencedirect.com/science/article/pii/S2666364326001578?dgcid=rss_sd_all
“Comparison of longitudinal and cumulative toxicity associated with targeted therapy versus chemotherapy for advanced EGFR-mutant NSCLC: post-hoc analysis of LUX-Lung 3.” JTO Clinical and Research Reports.
@article{article90117,
title = {Comparison of longitudinal and cumulative toxicity associated with targeted therapy versus chemotherapy for advanced EGFR-mutant NSCLC: post-hoc analysis of LUX-Lung 3},
journal = {JTO Clinical and Research Reports},
url = {https://www.sciencedirect.com/science/article/pii/S2666364326001578?dgcid=rss_sd_all}
}